SCHEMBL1879437

SCHEMBL1879437

COc1ccccc1Cn1c2c(c3cc(C#N)ccc31)CC(NC(=O)C(C)C)CC2

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 4/20 0.49
MTNR1B P49286 4/20 0.49
PTGDR2 Q9Y5Y4 1/20 0.43
ADORA2A P29274 1/20 0.40
ADORA1 P30542 1/20 0.40
XIAP P98170 3/20 0.40
FABP4 P15090 1/20 0.39
GPR6 P46095 1/20 0.38
KMT2A Q03164 1/20 0.38
RORC P51449 1/20 0.37
CYP1A2 P05177 1/20 0.37
MAPT P10636 1/20 0.37
CYP2C9 P11712 1/20 0.37
ALOX15 P16050 1/20 0.37
SCARB1 Q8WTV0 1/20 0.37
PLA2G4A P47712 1/20 0.37
LTB4R Q15722 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1881732 0.91 PTGDR2 (0.43) MTNR1AMTNR1BPTGDR2XIAPGPR6
SCHEMBL1876521 0.91 PTGDR2 (0.43) MTNR1AMTNR1BPTGDR2XIAPRORC
SCHEMBL1887084 0.89 PTGDR2 (0.43) MTNR1AMTNR1BPTGDR2XIAPRORC
SCHEMBL13478781 0.88 MTNR1A (0.51) MTNR1AMTNR1BPTGDR2FABP4KMT2A
SCHEMBL1876638 0.88 MTNR1A (0.51) MTNR1AMTNR1BPTGDR2XIAPFABP4
SCHEMBL1875284 0.88 PTGDR2 (0.42) MTNR1AMTNR1BPTGDR2XIAPRORC
SCHEMBL1879708 0.88 PTGDR2 (0.42) MTNR1AMTNR1BPTGDR2XIAPRORC
SCHEMBL1875281 0.88 PTGDR2 (0.42) MTNR1AMTNR1BPTGDR2XIAPRORC
SCHEMBL12636982 0.87 PTGDR2 (0.41) MTNR1AMTNR1BPTGDR2XIAPRORC
SCHEMBL1874237 0.87 PTGDR2 (0.43) MTNR1AMTNR1BPTGDR2XIAPFABP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7935722-B2 Tetrahydrocarbazole derivatives useful as androgen receptor modulators ELI LILLY AND COMPANY (US) 2011-05-03 US disclosed
US-7935722-B2 Tetrahydrocarbazole derivatives useful as androgen receptor modulators ELI LILLY AND COMPANY (US) 2011-05-03 US disclosed
US-7935722-B2 Tetrahydrocarbazole derivatives useful as androgen receptor modulators ELI LILLY AND COMPANY (US) 2011-05-03 US disclosed
EP-1902026-B1 TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS (SARM) LILLY CO ELI (US) 2010-02-17 EP disclosed
US-20100022550-A1 TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS CELLECTIS (FR) 2010-01-28 US disclosed
US-20100022550-A1 TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS CELLECTIS (FR) 2010-01-28 US disclosed
US-20100022550-A1 TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS CELLECTIS (FR) 2010-01-28 US disclosed
EP-1902026-A2 TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS (SARM) ELI LILLY AND COMPANY (US) 2008-03-26 EP disclosed
WO-2007002181-A2 TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS (SARM) ELI LILLY AND COMPANY (US) 2007-01-04 WO disclosed
WO-2007002181-A2 TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS (SARM) ELI LILLY AND COMPANY (US) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022550-A1 TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS AR, SHBG, CYP17A1 MTNR1A 1610/4885MTNR1B 1349/4885PTGDR2 437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.